LncRNA CASC19: a novel oncogene involved in human cancer.
Shidong WangChen QiaoRui FangShuyue YangGuiping ZhaoSi LiuPeng LiPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2023)
Multiple studies have shown that long non-coding RNAs (lncRNAs) play an important role in the occurrence and development of diverse cancers. Cancer susceptibility candidate 19 (CASC19), encoded by chromosome 8q24.21, is a newly discovered lncRNA that contains 324 nucleotides. CASC19 has been found to be significantly overexpressed in different human cancers, such as non-small cell lung carcinoma, gastric cancer, colorectal cancer, pancreatic cancer, clear cell renal cell carcinoma, glioma, cervical cancer, and nasopharyngeal carcinoma. Moreover, dysregulation of CASC19 was closely associated with clinicopathological parameters and cancer progression. CASC19 regulates a variety of cell phenotypes, including cell proliferation, apoptosis, cell cycle, migration, invasion, epithelial-mesenchymal transition, autophagy, and therapeutic resistance. In this study, we review recent studies on the characteristics and biological function of CASC19, as well as its role in human cancers. These findings suggest that CASC19 may be both a reliable biomarker and a potential therapeutic target in cancers.
Keyphrases
- cell cycle
- long non coding rna
- endothelial cells
- cell proliferation
- papillary thyroid
- epithelial mesenchymal transition
- cell death
- squamous cell
- childhood cancer
- endoplasmic reticulum stress
- signaling pathway
- pluripotent stem cells
- young adults
- risk assessment
- single cell
- gene expression
- squamous cell carcinoma
- pi k akt
- cell cycle arrest
- bone marrow
- human health
- mesenchymal stem cells
- genome wide